Key points are not available for this paper at this time.
The study showed that aged patients with a higher number of mutations than young patients have a higher risk of short survival. Senior patients with a more significant number of mutations have an increased risk of getting into the last cancer stage.
Siddalingappa et al. (Thu,) studied this question.